Business Context and Reporting Period
This Form 8-K is a current report filed by Nile Therapeutics, Inc. (not Capricor Therapeutics, Inc.) on August 6, 2009. The filing addresses a change in the company's independent registered public accounting firm.
Key Financial Metrics
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity for the current period. However, it references the financial condition of the company as of the most recent fiscal year-end:
- Revenue: The company has a lack of revenue.
- Profitability: The company has experienced recurring losses from operations.
- Going Concern: The prior auditor's report for the year ended December 31, 2008, included an explanatory paragraph stating that the lack of revenue and recurring losses raised substantial doubt about the company's ability to continue as a going concern.
Material Changes
The primary material change reported is the engagement of a new independent registered public accounting firm:
- New Auditor: Crowe Horwath LLP ("Crowe") was engaged on August 6, 2009.
- Reason for Change: The change resulted from the combination of the former auditor, Hays & Company LLP ("Hays"), with Crowe. The company took no action to dismiss Hays, and Hays did not resign; the transition occurred as a matter of law due to the firm merger.
- Continuity: The same Hays personnel who previously served the company will continue to serve under Crowe.
- Approval: The engagement was approved by the Audit Committee of the Board of Directors.
Guidance, Outlook, and Risks
Management Commentary and Risks:
- Going Concern Risk: The filing reiterates the substantial doubt regarding the company's ability to continue as a going concern, as noted in the 2008 audit report due to a lack of revenue and recurring losses.
- Auditor Disagreements: There were no disagreements with the former auditor (Hays) regarding accounting principles, financial statement disclosure, or auditing scope/procedures during the two most recent fiscal years or the interim period through August 6, 2009.
- Consultations: The company has not consulted with the new auditor (Crowe) regarding the application of accounting principles to specified transactions or the type of audit opinion that might be rendered.
Important Facts for Investor Verification
- Verify the company's current cash runway and capital raising efforts given the "substantial doubt" regarding its ability to continue as a going concern.
- Confirm that the transition to Crowe Horwath LLP does not result in any disruption to the audit process, as the same personnel are continuing the engagement.
- Review the letter from Hays & Company LLP (Exhibit 16.1) to ensure there are no undisclosed disagreements or reportable events.
- Note that the filing explicitly states the registrant is Nile Therapeutics, Inc., despite the metadata request referencing Capricor Therapeutics, Inc.